Alexion Pharmaceuticals Revenue, Growth & Competitor Profile

DBA ALEXION

Company Profile & Annual Report for Alexion Pharmaceuticals

Access the complete profile.

Alexion Pharmaceuticals Fast Facts

Revenue	Over $500 million    See Exact Annual Revenue
Employees	Over 1,000Exact Company Size
Primary Industry	5417 Scientific Research & Development Services
Additional NAICS Codes	325414 Biological Product Manufacturing
Address	121 Seaport Boulevard Boston, MA 02210

Alexion Pharmaceuticals's Annual Report & Profile shows critical firmographic facts:

• What is the company's size? (Annual sales and employees)
  • Alexion Pharmaceuticals's annual revenues are Over $500 million (see exact revenue data)
• What industry is the company in?
  • Alexion Pharmaceuticals is classified as operating in the Scientific Research & Development Services industry, NAICS Code 5417.

Alexion Pharmaceuticals is a publicly traded company on NMS using the ticker symbol ALXN. Detailed information on company financials and operating reports can be found here: NMS: ALXN

Alexion Pharmaceuticals Annual Revenue and Growth Rate

Alexion Pharmaceuticals	Revenue Est. ($ Million)	Growth Rate (%)	# Employees
2023	Over $500 million Details in Premium Report
2022
2021
2020
2019

1-Year Growth Rate: 3-Year Growth Rate (CAGR):

Note: Alexion Pharmaceuticals's revenues are gauged from an analysis of company filings.

Trademark Applications

Trademark applications show the products and services that Alexion Pharmaceuticals is developing and marketing. Alexion Pharmaceuticals doesn't have any recent trademark applications, indicating Alexion Pharmaceuticals is focusing on its existing business rather than expanding into new products and markets. Trademarks may include brand names, product names, logos and slogans.

Trademark	Date
KYADRI Pharmaceutical preparations for the treatment of hematological, nephrological, autoimmune, immunological, ocular, neurological and inflammatory related diseases and disorders	07/22/2022
APVARDI Pharmaceutical preparations for the treatment of hematological, nephrological, autoimmune, immunological, ocular, neurological and inflammatory related diseases and disorders	07/22/2022
VOYDEYA Pharmaceutical preparations for the treatment of hematological, nephrological, autoimmune, immunological, ocular, neurological and inflammatory related diseases and disorders	07/22/2022

See all trademarks and details in the Full Report.

Market Share of Alexion Pharmaceuticals's Largest Competitors

A competitive analysis shows these companies are in the same general field as Alexion Pharmaceuticals, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company	Headquarters	Revenue ($ MM)
LEIDOS	Denver, CO	100
NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA	Albuquerque, NM	30
INC RESEARCH	Raleigh, NC	27
RESEARCH FOUNDATION FOR STATE UNIVERSITY OF NEW YORK	Albany, NY	17
FLUOR MARINE PROPULSION	West Mifflin, PA	15
SYNEOS HEALTH	Raleigh, NC	13
ILLUMINA	San Diego, CA	12
UT-BATTELLE	Oak Ridge, TN	11
PRA HOLDINGS	Raleigh, NC	11

Nearby Competitors

These companies are similar in business line and location to Alexion Pharmaceuticals. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company	Headquarters	Revenue ($ MM)
VERTEX PHARMACEUTICALS	Boston, MA	100
ALEXION PHARMACEUTICALS	Boston, MA	57
MOTIONAL AD	Boston, MA	31
VERVE THERAPEUTICS	Boston, MA	11
PATHAI	Boston, MA	7
ODYSSEY THERAPEUTICS	Boston, MA	5

Future Competition: Alexion Pharmaceuticals's Fastest Growing Competitors

These companies are in the same general field as Alexion Pharmaceuticals and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

Company	Revenue ($ MM)